glipizide/metformin (Metaglip) (cont.)

Omudhome Ogbru, PharmD

Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

Charles Patrick Davis, MD, PhD

Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.

PREGNANCY: Glipizide/metformin has not been adequately evaluated in pregnant
women. Due to the lack of conclusive safety data, glipizide/metformin should be
avoided during pregnancy if possible. Glipizide/metformin is classified as FDA
pregnancy risk category C (animal reproduction studies have shown an adverse
effect on the fetus and there are no adequate and well-controlled studies in
humans, but potential benefits may warrant use of the drug in pregnant women
despite potential risks).

NURSING MOTHERS: It is not known if glipizide/metformin is excreted in breast
milk. Due to the lack of safety data and the potential risk for hypoglycemia in
the nursing infant, use of glipizide/metformin during breastfeeding is not
recommended.